Acute Lymphoblastic Leukemia
Conditions
Brief summary
An observatory for patients aged 18 years and over with Philadelphia chromosome positive (Ph+ or BCR::ABL1) acute lymphoblastic leukemia (ALL) and treated with the combination of BCR::ABL1 inhibitors and chemotherapy and/or corticosteroids and/or a monoclonal antibody.
Interventions
None listed
Sponsors
Versailles Hospital
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female patients ≥ 18 years 2. Philadelphia chromosome or BCR::ABL1 positive acute lymphoblastic leukaemia 3. Treatment with the combination of BCR::ABL1 inhibitors and chemotherapy and/or corticotherapy and/or a monoclonal antibody
Exclusion criteria
1. Patients deceded and having previously refused data collection 2. Not included in a prospective clinical trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival by 12 months | 12 months |
Secondary
| Measure | Time frame |
|---|---|
| overal survival by 36 months | 36 months |
| proportion of complete remission | 36 months |
| the molecular response defined by BCR//ABL1/ABL1 ratio in bone marrow and/or peripheral blood | 36 months |
| the molecular response defined by IGTR quantification proportion in bone marrow and/or peripheral blood | 36 months |
| Event free survival | 36 months |
| Relapse free survival | 36 months |
| the incidence ofBCR..ABL1 TK mutations | 36 months |
| treatment tolerance | 36 months |
| Death during induction | 2 months |
| Death in complete remission | 36 months |
Countries
France
Contacts
CONTACTSandrine Roux
Outcome results
None listed